Results 51 to 60 of about 4,064 (194)

New approaches in the diagnosis and treatment of latent tuberculosis infection [PDF]

, 2010
With nearly 9 million new active disease cases and 2 million deaths occurring worldwide every year, tuberculosis continues to remain a major public health problem. Exposure to Mycobacterium tuberculosis leads to active disease in only ~10% people.
Suhail Ahmad
core   +1 more source

First evaluation of the performance of portable IGRA, QIAreach® QuantiFERON®-TB in intermediate TB incidence setting.

PLoS ONE, 2023
Diagnosis and treatment of tuberculosis infection (TBI) are the core elements of tuberculosis elimination. Interferon gamma release assays have advantages over the tuberculin skin test, although their implementation in low-resource settings is ...
Zirwatul Adilah Aziz, Noorliza Mohamad Noordin, Wan Mazlina Wan Mohd, Mohd Amin Kasim   +3 more
doaj   +1 more source

A systematic review of economic models used to assess the cost-effectiveness of strategies for identifying latent tuberculosis in high-risk groups [PDF]

, 2016
Timely diagnosis and treatment of latent tuberculosis infection (LTBI) through screening remains a key public health priority. Although globally it is recommended to screen people at high risk of developing TB, the economic evidence underpinning these ...
Auguste, Peter, Court, Rachel A., Pink, Joshua, Tsertsvadze, Alexander   +3 more
core   +1 more source

QuantiFERON-TB gold plus in liver transplant candidates: single-center experience

Gastroenterology & Hepatology: Open Access, 2022
Background/Objectives: Latent tuberculosis infection (LTBI) screening prior to orthotopic liver transplant (OLT) is essential. The data on QuantiFERON-TB -Gold Plus (QFT-Plus) in OLT candidates is scarce. Methods: QFT-Plus results performed prior to transplant among OLT recipients transplanted between 4/2019 and 8/2020 were evaluated.
Jacques Simkins, Maria A Mendoza Maria A Mendoza, Gabriel Motoa, Aditya Chandorkar Aditya Chandorkar, Yoichiro Natori, Shweta Anjan, Leopoldo R Arosemena, Rodrigo Vianna Rodrigo Vianna   +7 more
openaire   +1 more source

Implementing contact tracing for tuberculosis in Kyrgyz Republic and risk factors for positivity using QuantiFERON-TB Gold plus

BMC Infectious Diseases, 2020
Background Effective active case finding (ACF) activities are essential for early identification of new cases of active tuberculosis (TB) and latent TB infection (LTBI).
Caroline Corbett, Aizat Kulzhabaeva, Tatjana Toichkina, Gulmira Kalmambetova, Sevim Ahmedov, Uladzimir Antonenka, Altyn Iskakova, Dilorom Kosimova, Dasha Migunov, Bakyt Myrzaliev, Evgeni Sahalchyk, Nagira Umetalieva, Monica Vogel, Abdylat Kadyrov, Harald Hoffmann   +14 more
doaj   +1 more source

The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection [PDF]

, 2014
Psoriatic arthritis (PsA) is an inflammatory arthropathy associated with skin and/or nail psoriasis. TNF-α is an essential cytokine for the host defense, and its depletion by treatment may facilitate the risk of infections or their reactivation.
Alessandro Matarese, Alessandro Sanduzzi, Antonio Del Puente, Francesco Caso, Luca Cantarini, Luisa Costa, Maria Luisa Bocchino, Mariangela Atteno, Raffaele Scarpa   +8 more
core   +1 more source

Effect of isoniazid preventive therapy on immune responses to mycobacterium tuberculosis: an open label randomised, controlled, exploratory study. [PDF]

, 2015
BACKGROUND: With the renewed emphasis to implement isoniazid preventive therapy (IPT) in Sub-Saharan Africa, we investigated the effect of IPT on immunological profiles among household contacts with latent tuberculosis.
Biraro, Irene Andia, Cose, Stephen, Dockrell, Hazel M, Egesa, Moses, Elliott, Alison M, Joloba, Moses, Katamba, Achilles, Kimuda, Simon, Levin, Jonathan, Smith, Steven G, Toulza, Frederic   +10 more
core   +1 more source

Performance of QuantiFERON-TB Gold Plus assays in paediatric tuberculosis: a multicentre PTBNET study

Thorax, 2022
RationaleIn 2016, a new interferon-gamma release assay (IGRA) was introduced, QuantiFERON-TB Gold Plus (QFT-Plus), claimed to have improved sensitivity in active tuberculosis (TB).ObjectivesThis study aimed to determine the performance of QFT-Plus, compared with previous generation IGRAs and the tuberculin skin test (TST), in children with TB in Europe.
Buonsenso, Danilo, Noguera-Julian, Antoni, Moroni, Rossana, Hernández-Bartolomé, Angel, Fritschi, Nora, Lancella, Laura, Cursi, Laura, Soler-Garcia, Aleix, Krüger, Renate, Feiterna-Sperling, Cornelia, Sali, Michela, Lo Vecchio, Andrea, Scarano, Sara, Hernanz Lobo, Alicia, Espiau, Maria, Soriano-Arandes, Antonio, Cetin, Benhur Sirvan, Brinkmann, Folke, Ozere, Iveta, Baquero-Artigao, Fernando, Tsolia, Maria, Milheiro Silva, Tiago, Bustillo-Alonso, Matilde, Martín Nalda, Andrea, Mancini, Margherita, Starshinova, Anna, Ritz, Nicole, Velizarova, Svetlana, Ferreras-Antolín, Laura, Götzinger, Florian, Bilogortseva, Olga, Chechenyeva, Vira, Tebruegge, Marc, Santiago-García, Begoña, Ptbnet QFT-Plus study group   +34 more
openaire   +7 more sources

Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes (BSPED) and the Association of British Clinical Diabetologists (ABCD)

Diabetic Medicine, EarlyView.
Abstract Introduction In 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of teplizumab (a monoclonal anti‐CD3 antibody) to delay progression from Stage 2 to Stage 3 Type 1 diabetes in the UK. Methods To address the need for clear guidance on managing patients eligible for teplizumab therapy, the British Society of ...
Renuka P. Dias, M. Loredana Marcovecchio, Ruben H. Willemsen, Fiona Campbell, Ahmad Ashour, Philip Newland‐Jones, Jennifer Cooper, Parth Narendran, Neil P. Wright   +8 more
wiley   +1 more source

Comparative evaluation of QuantiFERON-TB gold in-tube plus for Mycobacterium tuberculosis infection among adolescents in China

BMC Public Health
Summary To our knowledge, this is the first head-to-head study to evaluate QuantiFERON-TB Gold Plus, QuantiFERON-TB Gold In-Tube, ESAT6-CFP10, and tuberculin skin test among adolescents.
Peng Lu, Leonardo Martinez, Hao Xue, Qiao Liu, Xiaoyan Ding, Jingjing Pan, Hui Ding, Wei Lu, Limei Zhu, Jiangming Wang   +9 more
doaj   +1 more source